Alcaftadine (Lastacaft)

Trade Name : LASTACAFT

Allergan, Inc.

SOLUTION/ DROPS

Strength 2.5 mg/mL

Storage and handling for LASTACAFT

ALCAFTADINE Histamine H1 Receptor Antagonists [MoA],Histamine-1 Receptor Antagonist [EPC]

Disclaimer

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Alcaftadine (Lastacaft) which is also known as LASTACAFT and Manufactured by Allergan, Inc.. It is available in strength of 2.5 mg/mL per ml. Read more

Alcaftadine (Lastacaft) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

About GNH

No data

No data

Contraindications, Hypersensitivity () 12/2014n

LASTACAFT is an H histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.n
LASTACAFT is an H histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. ()n

Instill one drop in each eye once daily. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.n
Instill one drop in each eye once daily. ()n

Topical ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL).n
Ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL) ()n

LASTACAFT is contraindicated in patients with hypersensitivity to any component in the product.n
Hypersensitivity. ()n

No data

To minimize the risk of eye injury and contamination, do not touch dropper tip to eyelids and surrounding areas, or any other surface. Keep bottle tightly closed when not in use. ()n
n LASTACAFT should not be used to treat contact lens-related irritation. ()n
Remove contact lenses prior to instillation of LASTACAFT. ()n

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.n
The most common ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT, were eye irritation, burning and/or stinging on instillation, eye redness, and eye pruritus. ()n

No data

LASTACAFT is a sterile, topically administered H receptor antagonist containing alcaftadine for ophthalmic use.n
Alcaftadine is a white to yellow powder with an empirical formula of CHNO and a molecular weight of 307.39.n
Contains:
Active:
Inactives:
Chemical Name:n- H
Structural Formula:
The drug product has a pH of approximately 7 and an osmolality of approximately 290 mOsm/kg.n

No data

Alcaftadine was not mutagenic or genotoxic in the Ames test, the mouse lymphoma assay or the mouse micronucleus assay.n
Alcaftadine was found to have no effect on fertility of male and female rats at oral doses up to 20 mg/kg/day (approximately 200 times the plasma exposure at the recommended human ocular dose).n

Clinical efficacy was evaluated in conjunctival allergen challenge (CAC) studies. LASTACAFT was more effective than its vehicle in preventing ocular itching in patients with allergic conjunctivitis induced by an ocular allergen challenge, both at 3 minutes post-dosing and at 16 hours post-dosing of LASTACAFT.n
The safety of LASTACAFT was evaluated in a randomized clinical study of 909 subjects over a period of 6 weeks.n

n LASTACAFT (alcaftadine ophthalmic solution) 0.25% is supplied in an opaque, white low-density polyethylene bottle with a white polystyrene cap. n
3 mL fill in 5 mL bottle u00a0 u00a0 u00a0 u00a0NDC 0023-4290-03n
Storage:

No data

NDC 0023-4290-03n n (alcaftadine ophthalmicsolution) 0.25%n Sterilen n

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.